4-Chloro-6-Iodoquinazoline CAS 98556-31-1 Puritas >98.0% (HPLC)
Shanghai Ruifu Chemical Co., Ltd. est primarius fabrica 4-Chloro-6-Iodoquinazolini (CAS: 98556-31-1) cum qualitate magna.Ruifu Chemical traditio totius terrarum, quantitatis competitive pretium, optimum servitium, parvas et moles in promptu habere potest.Purchase 4-Chloro-6-Iodoquinazoline;Please contact: alvin@ruifuchem.com
Nomen chemicum | 4-Chloro-6-Iodoquinazoline |
Synonyma | 6-Iodo-4-Chloroquinazoline |
Stock Status | In Stock, Commercial Productio |
CAS Number | 98556-31-1 |
Formulae hypotheticae | C8H4ClIN2 |
M. Pondus | 290.49 g/mol |
Liquescens punctum | 175.0 ad 179.0℃ |
Density | 2.017±0.06 g/cm3 |
Index refractivus n20/D | 1.739 |
Sensitiva | Aer Sensitiva |
COA & MSDS | Praesto |
Origin | Shanghai, China |
Brand | Ruifu Chemical |
Items | Signa inspectionis | Proventus |
Aspectus | Terra Yellow ad Yellowish-brunneis pulveris | Terra Yellow Pulvis |
Liquescens punctum | 175.0 ad 179.0℃ | 177.2℃ |
Damnum in Siccatio | <1.00% | 0.15% |
Puritas / Analysis Methodus | >98.0% (HPLC) | 98.43% |
1H NMR Imaginum | Congruunt Structure | Obsequitur |
conclusio | Productum probatum est et cum datis specificationibus obsequitur | |
Applicationem | Ditosylate Monohydratorum |
Sarcina:Fluorinated Utrem, aluminium ffoyle, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Continentem arcte clausam et in frigido, sicco et bene ventilato horreis a substantiis incompossibilibus repone.A luce et humore protege.
Naviportans:Libera ad mundum ab aere, per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
4-Chloro-6-Iodoquinazoline (CAS: 98556-31-1) medium est in synthesi Lapatinib (CAS: 231277-92-2) / Lapatinib Ditosylate Monohydratorum (CAS: 388082-78-8).
Lapatinib novum cancer pectoris iaculis theraphim medicamentum evolvit et fabricatum est a GlaxoSmithKline, quod ab administratione US Cibus et medicamentis die XIII Martii MMVII probatum est. Praesens probatus indicatio coniungitur cum capecitabine ad cancrum pectus provectum vel metastaticum, et aegri cancer pectus aliis medicamentis prima linea tractanda est.Nomen artis eius in Civitatibus Foederatis Americae est Tykerb.Die 14 Decembris 2007, Medicinae Europaeae Agency (EMEA) enumerationem Lapatinib in Europa sub commercii nomine Tyverb approbaverunt.Theraphim hypotheticum iaculis pro cancro mammae ad tractationem oncogenis pertinentia et expressio producta cognata ad eventum et progressionem cancri pectoris.Medicamenta hypothetica iaculis inhibent vel occidunt cellulas tumores obcludunt translationi signo in cellulis tumore vel cellulis affinibus ad mutationes in locutionibus e gene cellularum coercendis.Lapatinib est oralis augmenti minoris moleculi epidermalis factor tyrosini kinasi inhibitoris.Fuscae probationes ostenderunt pro aegris cancer pectoris HER2 qui resistentiam evolvit ad Roche Herceptin (Herceptin), Lapatinib bonum effectum clinicum habet.In vitro probat, Lapatinib notabile incrementum inhibitorium effectum in Her-2 superexpressio carcinomatis cellae lineae pectoris habuit.In Phase I tentamenta carcinomatis carcinomatis provecti cum her-2 overexpressione, Lapatinib etiam magnum ratem efficacem habet et cum Herceptin transversim non resistit (trastuzumab).Quia structura eius parva est moleculae, dissimile Herceptin (trastuzumab), obice potest penetrare sanguinem cerebri et quendam effectum medicinalem in metastasi cerebri cancri pectoris habet.
-
Lapatinib Base CAS 231277-92-2 Puritas ≥99.0% (H...
-
Lapatinib Ditosylate Monohydrate CAS 388082-78-...
-
3-Chloro-4-(3-Fluorobenzyloxy)aniline CAS 20219...
-
4-Chloro-6-Iodoquinazoline CAS 98556-31-1 Purit...
-
Sodium Methanesulfinate CAS 20277-69-4 Munditia >...
-
2-Aminoethyl Methyl Sulfone Hydrochloride CAS 1...
-
6-Iodo-4-Hydroxyquinazoline CAS 16064-08-7 Puri...
-
5-Formyl-2-Furanboronic Acidum CAS 27329-70-0 Pur...
-
Lapatinib Intermediate CAS 231278-84-5 Puritas >...